Joyce Fingeroth to Male
This is a "connection" page, showing publications Joyce Fingeroth has written about Male.
Connection Strength
0.057
-
Ogembo JG, Milner DA, Mansfield KG, Rodig SJ, Murphy GF, Kutok JL, Pinkus GS, Fingeroth JD. SIRPa/CD172a and FHOD1 are unique markers of littoral cells, a recently evolved major cell population of red pulp of human spleen. J Immunol. 2012 May 01; 188(9):4496-505.
Score: 0.023
-
Dugan JP, Haverkos BM, Villagomez L, Martin LK, Lustberg M, Patton J, Martin M, Huang Y, Nuovo G, Yan F, Cavaliere R, Fingeroth J, Kenney SC, Ambinder RF, Lozanski G, Porcu P, Caligiuri MA, Baiocchi RA. Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. Clin Cancer Res. 2018 07 15; 24(14):3273-3281.
Score: 0.009
-
Daily J, Werner B, Soiffer R, Fingeroth J. IGIV: a potential role for hepatitis B prophylaxis in the bone marrow peritransplant period. Bone Marrow Transplant. 1998 Apr; 21(7):739-42.
Score: 0.009
-
Bowles SL, Jaeger C, Ferrara C, Fingeroth J, Van De Venter M, Oosthuizen V. Comparative binding of soluble fragments (derCD23, sCD23, and exCD23) of recombinant human CD23 to CD21 (SCR 1-2) and native IgE, and their effect on IgE regulation. Cell Immunol. 2011; 271(2):371-8.
Score: 0.006
-
Perrine SP, Hermine O, Small T, Suarez F, O'Reilly R, Boulad F, Fingeroth J, Askin M, Levy A, Mentzer SJ, Di Nicola M, Gianni AM, Klein C, Horwitz S, Faller DV. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007 Mar 15; 109(6):2571-8.
Score: 0.004
-
Oram RJ, Marcellino D, Strauss D, Gustafson E, Talarico CL, Root AK, Sharma PL, Thompson K, Fingeroth JD, Crumpacker C, Herold BC. Characterization of an acyclovir-resistant herpes simplex virus type 2 strain isolated from a premature neonate. J Infect Dis. 2000 Apr; 181(4):1458-61.
Score: 0.003
-
Vance EA, Soiffer RJ, McDonald GB, Myerson D, Fingeroth J, Ritz J. Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation. 1996 Nov 15; 62(9):1358-60.
Score: 0.002
-
Shuhart MC, Myerson D, Childs BH, Fingeroth JD, Perry JJ, Snyder DS, Spurgeon CL, Bevan CA, McDonald GB. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood. 1994 Nov 01; 84(9):3229-35.
Score: 0.002